<DOC>
	<DOCNO>NCT01898377</DOCNO>
	<brief_summary>In study combine mycophenolate mofetil imatinib mesylate treat steroid-refractory sclerotic/fibrotic type chronic graft-versus-host disease ( GVHD ) see response rate find safety combination .</brief_summary>
	<brief_title>Imatinib Mesylate Mycophenolate Mofetil Steroid-Refractory Sclerotic/Fibrotic cGVHD Children</brief_title>
	<detailed_description>Sclerotic/fibrotic type chronic GVHD one severe form disease frequently refractory standard treatment approach . Imatinib mesylate , tyrosine kinase inhibitor , show effective patient sclerotic/fibrotic type chronic GVHD strongly inhibit PDGF ( Platelet-derived growth factor ) TGF-β ( transform growth factor-β ) intracellular signal , responsible expression extracellular matrix gene . Mycophenolate mofetil ( MMF ) one effective agent treatment chronic graft-versus-host disease . MMF rapidly absorb oral administration hydrolyze active metabolite , MPA ( mycophenolic acid ) . MPA selectively inhibit inosine monophosphate dehydrogenase , block pathway purine synthesis T B lymphocytes . In study combine MMF imatinib mesylate treat steroid-refractory sclerotic/fibrotic type chronic GVHD see response rate find safety combination .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Inclusion criterion Patients must diagnosis chronic GVHD fibrotic/sclerodermalike feature . This diagnosis make clinically histopathology . Patients must active disease least one follow manifestation : skin sclerosis , symptomatic bronchiolitis obliterans , extensive lung fibrosis , pathologically demonstrated visceral fibrotic involvement gut . Patients corticosteroid refractory dependant cGVHD eligible . Steroidrefractory chronic GVHD define chronic GVHD sustain severity last full month patient receive equivalent prednisone 0.5 mg/kg per day 1 mg/kg every day . Age 21 year old Exclusion criterion Patients chemotherapy , radiotherapy within 4 week prior enter study . Patients recover adverse event . Prior treatment imatinib mesylate tyrosine kinase inhibitor date transplant . Patients pregnancy lactate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Chronic graft-versus-host disease</keyword>
</DOC>